Harrow Health, Inc. logo HROW - Harrow Health, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 10
HOLD 0
SELL 0
STRONG
SELL 0
| PRICE TARGET: $73.67 DETAILS
HIGH: $88.00
LOW: $63.00
MEDIAN: $70.00
CONSENSUS: $73.67
UPSIDE: 123.24%

Stock News

HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations

HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations

MONSEY, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Harrow, Inc. (Nasdaq: HROW) (“HROW”) has violated the federal securities laws after the company advised that VEVYE revenue of $20.9 million during the first quarter of 2026 was below expectations due to an estimated $8 million gross-to-net reduction associated with new commercial coverage for VEVYE.

May 13, 2026 06:13 AM • globenewswire.com
Harrow Announces First Quarter 2026 Financial Results

Harrow Announces First Quarter 2026 Financial Results

First Quarter 2026 and Selected Highlights:  VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category) VEVYE demand growth on track to deliver 2026 revenue of over $100 million Quarterly revenue of $44.2 million, including a non-recurring gross-to-net revenue adjustment connected to new VEVYE commercial coverage, which lowered Q1 revenue by approximately $8 million IHEEZO® unit demand increased 18% year-over-year, with 82% of units from retina accounts TRIESENCE® unit demand more than doubled year-over-year, the sixth consecutive quarter of growth Second Quarter revenue expected between $71 million and $81 million Full-year 2026 revenue guidance reaffirmed at $350 million to $365 million Cash and cash equivalents of $94.6 million as of March 31, 2026 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn.

May 11, 2026 12:05 PM • globenewswire.com
Harrow: Now Is The Buy Time

Harrow: Now Is The Buy Time

Harrow has delivered a decade-long 40% CAGR in revenue, with robust operating leverage and EBITDA margin expansion. Seasonal weakness in Q1 consistently creates compelling entry points, with share prices typically bottoming near the Q1 report date and rebounding sharply later in the year. HROW's 2026 low of $33 suggests a likely move to $100 within the year, reflecting the historical pattern of annual highs being about 3x annual lows.

Apr 20, 2026 03:30 AM • seekingalpha.com
Harrow: Probably A Short-Term Market Overreaction

Harrow: Probably A Short-Term Market Overreaction

Harrow is rated a 'Strong Buy' with a fair value of $73.25, implying 104% upside from current levels (~$35.90). I project robust long-term growth driven by Vevye, Iheezo, and pipeline assets, despite recent short-term guidance disappointment and market volatility. I model a bit conservatively, with peak sales, a 32–45% EBIT margin for 2029–2035, and an 11.3% WACC, giving undervaluation even under some risk scenarios.

Apr 14, 2026 01:33 AM • seekingalpha.com
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth

Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth

NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer, subject to market and certain other conditions, an additional $50.0 million in aggregate principal amount of its 8.625% senior unsecured notes due 2030 (the "2030 Notes"). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that guarantees or co-issues any of its indebtedness or any indebtedness of any of its subsidiaries that guarantees the 2030 Notes, subject to certain exceptions. The 2030 Notes will be issued as additional notes under the same indenture governing the $250,000,000 aggregate principal amount of 2030 Notes that were issued on September 12, 2025 (the “Existing Notes”), will be treated as a single series with the Existing Notes and will have the same terms as the Existing Notes other than with respect to the date of issuance and the issue price.

Mar 24, 2026 04:15 AM • globenewswire.com
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

NASHVILLE, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that three scientific abstracts highlighting its commercial products VEVYE® (cyclosporine ophthalmic solution) 0.1% and ILEVRO® (nepafenac ophthalmic suspension) 0.3% have been accepted for presentation at the American Society of Cataract and Refractive Surgery (ASCRS) 2026 Annual Meeting, taking place April 10–13 at the Walter E. Washington Convention Center in Washington, D.C.

Mar 18, 2026 03:00 AM • globenewswire.com
Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market

Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market

Harrow, Inc. is rapidly evolving into a dominant US ophthalmic pharma player, with a 30-fold revenue increase since 2015 and strong operating leverage. HROW's recent 35% stock pullback post-Q4 2025 is attributed to conservative 2026 guidance, not deteriorating fundamentals, presenting a compelling buying opportunity. Vevye and Iheezo, HROW's flagship drugs, are set for significant revenue acceleration through expanded insurance coverage, salesforce doubling, and clinical trial catalysts.

Mar 17, 2026 10:00 AM • seekingalpha.com

Price Targets